Our findings suggest that epigenetic DNMT3A silencing of ANRIL enhances liver fibrosis and HSC activation through activating AMPK pathway, and offer a novel approach for liver fibrosis therapy. This evidence concerns the gene DNMT3A and Hepatic fibrosis.